KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Operating Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Operating Margin for 4 consecutive years, with 719.61% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Operating Margin fell 54427.0% year-over-year to 719.61%, compared with a TTM value of 623.82% through Dec 2023, down 66842.0%, and an annual FY2024 reading of 1091.69%, down 46787.0% over the prior year.
  • Operating Margin was 719.61% for Q4 2023 at AbCellera Biologics, up from 831.93% in the prior quarter.
  • Across five years, Operating Margin topped out at 77.97% in Q1 2021 and bottomed at 831.93% in Q3 2023.
  • Average Operating Margin over 4 years is 192.13%, with a median of 22.28% recorded in 2021.
  • The sharpest move saw Operating Margin skyrocketed 54731bps in 2022, then plummeted -86915bps in 2023.
  • Year by year, Operating Margin stood at 77.33% in 2020, then fell by -24bps to 58.53% in 2021, then crashed by -400bps to 175.34% in 2022, then tumbled by -310bps to 719.61% in 2023.
  • Business Quant data shows Operating Margin for ABCL at 719.61% in Q4 2023, 831.93% in Q3 2023, and 511.03% in Q2 2023.